Cosmetic Peptides

Argireline (Acetyl Hexapeptide-8)

For Research Use Only. Not for Human or Veterinary Use.

Overview

Argireline is Acetyl Hexapeptide-8, a synthetic neuromodulatory peptide (Ac-EEMQRR-NH₂) modelled on the N-terminal end of SNAP-25, a protein in the machinery that releases neurotransmitters. In topical research it is studied as a way to reduce the micro-contractions behind dynamic expression lines — a mechanism often described as a topically-applied research alternative to injectable approaches. Its ends are capped (N-acetyl, C-amide) so it resists the enzymes that would otherwise trim a short peptide.

Chemical Profile

PropertyValue
CAS number616204-22-9
INCI nameAcetyl Hexapeptide-8 (formerly Acetyl Hexapeptide-3)
Amino-acid sequenceAc-Glu-Glu-Met-Gln-Arg-Arg-NH₂
One-letter codeAc-EEMQRR-NH₂
Molecular formulaC₃₄H₆₀N₁₄O₁₂S
Molecular weight888.47 g/mol
Purity (HPLC)≥ 98%
AppearanceWhite to off-white lyophilized powder
Argireline at a glance
Class
Neuromodulatory peptide (SNARE inhibitor)
Origin
Modelled on the SNAP-25 N-terminus
Research status
Extensive clinical research
Typical route
Topical
Reference trade name
Argireline™ (Lipotec)
Key feature
Studied for topical reduction of muscle micro-contraction

Mechanism of Action

Nerve endings release acetylcholine by fusing vesicles to the cell membrane, and that fusion depends on the SNARE complex assembling correctly. Argireline is studied as a fragment that resembles part of SNAP-25, one of the SNARE proteins, and is investigated for competing with it during assembly. The result explored in models is a softer signal for muscle contraction — the peptide is described as acting downstream of calcium entry rather than blocking calcium itself.

ComponentResearch description
Primary targetThe SNARE assembly (SNAP-25 / syntaxin / VAMP interaction).
Inhibition modeStudied as competitive interference at the SNAP-25 N-terminal region.
NeurotransmitterAssociated with reduced acetylcholine release at the neuromuscular junction.
Downstream effectExplored as decreased muscle-contraction amplitude in models.
Calcium dependenceReported to act after Ca²⁺ influx, not on the calcium signal itself.

Areas where the topical effect is typically studied: expression lines generally, the periorbital area (crow’s-feet region), and forehead lines.

Pharmacology

ParameterValue
logP−1.7 (hydrophilic)
pKa≈ 12.5 (arginine guanidinium), 4.0 (glutamic acid)
Topical bioavailability~2–5% (usually needs penetration enhancers or liposomes)
StabilityHigh — capped N-acetyl and C-amide ends resist exopeptidases
Protein bindingLow to moderate
MetabolismProteolytic breakdown in the epidermis
Route of administrationTopical

Research Evidence

Argireline is the most-studied topical neuromodulatory peptide and is the usual comparator for newer analogues such as SNAP-8, with both mechanistic (preclinical) and human (clinical) studies.

Expression-line research

Central to topical research on dynamic expression lines and periorbital/forehead areas.

SNARE biology

A model tool for studying peptide interference with vesicle-fusion machinery.

Formulation studies

Investigated for delivery, since a hydrophilic peptide needs help crossing the stratum corneum.

Combination research

Frequently paired with matrikines (e.g. Matrixyl) in multi-mechanism formulation studies.

Preclinical research — representative models and what they investigate:

ModelResearch focusReference
SNAP-25 competitive binding assayInterference with SNARE assemblyBlanes-Mira C, et al. (2002)
Neuronal cell model (PC12)Stimulated neurotransmitter releaseSchagen SK (2017, review)
Nerve–muscle preparationMuscle-contraction amplitudeBlanes-Mira C, et al. (2002)
Human skin (ex vivo)Peptide penetrationGorouhi F, Maibach HI (2009)

Clinical research — the types of human study in which the ingredient is examined:

Study typeEndpoints studiedReference
Topical solution / creamExpression-line and crow’s-feet appearanceBlanes-Mira C, et al. (2002)
Anti-aging formulationsWrinkle roughness and depthLupo MP, Cole AL (2007)

Representative reported directions from the literature (qualitative; GLP-1 entries reflect published clinical-trial results, others are reported study directions, not restated as precise product claims):

Reported direction / findingContextReference
Interferes with SNARE assembly, reducing neurotransmitter releaseSNAP-25 / neuronal modelsBlanes-Mira C et al., 2002
Reduced appearance of expression linestopical human studyBlanes-Mira C et al., 2002

For laboratory research and cosmetic formulation study only. Descriptions refer to published research contexts and are not product or health claims.

Formulation & Dosing Reference

ParameterValue
Typical topical concentration1–10% (w/w)
Common working range5–10%
Solubility in water≥ 50 mg/mL
Solubility in ethanolModerate (≈ 10 mg/mL)
Solubility in DMSO≥ 50 mg/mL
Recommended formulation pH5.0–7.0
Storage (powder)2–8°C, sealed, dry, protected from light
  • The EU cosmetic-ingredient database lists a maximum use level of 10% for this ingredient.
  • The single methionine residue can oxidise in solution; antioxidants (e.g. BHT, tocopherol) are commonly added to formulations.

Safety Profile

AssessmentReported result
Acute oral toxicity (rat)LD50 > 2000 mg/kg
Dermal irritation (rabbit)Non-irritant at 10%
Ocular irritation (rabbit)Non-irritant
Skin sensitization (GPMT)Non-sensitizing
Mutagenicity (Ames)Negative
Maximum use level (EU CosIng)10%
INCI statusApproved cosmetic ingredient (Acetyl Hexapeptide-8)

Physicochemical Properties

PropertyValue
AppearanceWhite to off-white lyophilized powder
Solubility in water≥ 50 mg/mL
Solubility in DMSO≥ 50 mg/mL
Melting point> 200°C (decomposition)
pH (1% aqueous)5.0–6.0
Isoelectric point (pI)≈ 10.8
Net charge at pH 7≈ +2
Light sensitivityLow

Synthesis & Manufacturing

Argireline is built by solid-phase peptide synthesis on an amide resin so the finished peptide carries a C-terminal amide, then acetylated at the N-terminus. The two arginines in a row and the oxidation-prone methionine make coupling and cleavage the parts that need the most care.

StepDetail
StrategySolid-phase peptide synthesis, Fmoc/tBu chemistry
ResinRink amide MBHA resin (C-terminal amide)
CouplingHATU / HBTU with DIPEA
Side-chain protectionGlu(OtBu), Gln(Trt), Arg(Pbf); Met unprotected
N-terminal acetylationAcetic anhydride / DIPEA after final Fmoc removal
CleavageTFA / TIPS / H₂O (95 : 2.5 : 2.5), with scavengers
PurificationPreparative RP-HPLC (C18, TFA/ACN gradient)
  • The consecutive Arg-Arg often needs extended or double coupling because of steric hindrance.
  • Methionine can oxidise during cleavage; scavengers such as TIPS or thioanisole limit sulfoxide formation.
  • Complete N-acetylation is checked as a characteristic +42 Da mass shift and the loss of the free N-terminal amine peak.

Analytical Methods

MethodPurposeTypical result
RP-HPLC (C18, UV 214 nm)Purity≥ 98%
ESI-MS (positive mode)Identity / massm/z consistent with the acetylated hexapeptide amide
Amino-acid analysisCompositionGlu₂ : Met : Gln : Arg₂
LC-MS/MSEnd-group confirmationN-acetylation and C-amidation confirmed
RP-HPLCMethionine sulfoxideOxidised species kept low
Ion chromatographyResidual TFAKept low

Representative RP-HPLC purity method:

  • Column: C18, 5 µm, 250 × 4.6 mm
  • Mobile phase A: 0.1% TFA in water · Mobile phase B: 0.1% TFA in acetonitrile
  • Gradient: 5–30% B over ~20 min · Flow rate: 1.0 mL/min
  • Detection: UV 214 nm

Stability Data

The capped ends make Argireline stable as a powder and in finished products; the main thing to manage is oxidation of the single methionine residue in solution.

ConditionDurationResult
Lyophilized powder, 2–8°C, dark≥ 24 monthsNo significant degradation
Lyophilized powder, 25°C, dark≥ 12 monthsMinimal; low Met oxidation
Aqueous solution, pH 5.5, 4°C, dark≈ 14 daysMinor degradation
Aqueous solution, pH 5.5, 25°C≈ 7 daysMinor degradation
Formulated serum / cream, 25°C12+ monthsPeptide largely retained
Light exposure (ICH Q1B)StandardLight-stable
Freeze–thaw (−20°C ⇄ 25°C)3 cyclesAcceptable
  • Both the acetylated N-terminus and amidated C-terminus resist exopeptidase cleavage, giving good stability.
  • The single methionine can oxidise to methionine sulfoxide in warm solution; antioxidants (BHT, tocopherol) are commonly added.
  • Optimal stability is pH 5.0–7.0; avoid strong oxidising agents in formulation.

Selected References

Representative peer-reviewed literature on Acetyl Hexapeptide-8 (Argireline). Listed for research reference.

  • Blanes-Mira C, et al. A synthetic hexapeptide (Argireline) with antiwrinkle activity. International Journal of Cosmetic Science, 2002.
  • Gorouhi F, Maibach HI. Role of topical peptides in preventing or treating aged skin. International Journal of Cosmetic Science, 2009.
  • Lupo MP, Cole AL. Cosmeceutical peptides. Dermatologic Therapy, 2007.
  • Schagen SK. Topical peptide treatments with effective anti-aging results. Cosmetics, 2017.

Quality & Supply

  • HPLC ≥ 98% purity with a Certificate of Analysis per batch
  • Identity confirmed by LC-MS; end-group modifications verified
  • Research samples through to bulk, with worldwide delivery
  • Custom sequences and packaging on request

Need Argireline — sample or bulk?

HPLC-verified, COA per batch. Tell us the quantity you need.

Request a Quote